uPAR PET/CT for Prognostication and Response Assessment in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing Radium-223 Therapy: A Prospective Phase II Study

The aim of this Phase II study was to investigate the potential for response assessment and prognostication of positron emission tomography (PET) using the ligand (68)Ga-NOTA-AE105 targeting the urokinase-type plasminogen activator receptor (uPAR) in patients receiving Radium-223-dichloride therapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Fosbøl, Marie Øbro, Mortensen, Jann, Petersen, Peter Meidahl, Loft, Annika, Madsen, Jacob, Kjaer, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8232164/
https://www.ncbi.nlm.nih.gov/pubmed/34198666
http://dx.doi.org/10.3390/diagnostics11061087

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8232164/
https://www.ncbi.nlm.nih.gov/pubmed/34198666
http://dx.doi.org/10.3390/diagnostics11061087

Ejemplares similares